MARI — Marinomed Biotech AG Cashflow Statement
0.000.00%
- €22.05m
- €50.23m
- €9.18m
Annual cashflow statement for Marinomed Biotech AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -7.22 | -6.01 | -5.89 | -6.4 | -6.79 |
Depreciation | |||||
Non-Cash Items | 1.82 | 0.443 | 1.58 | 1.43 | 1.62 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -2.57 | -1.75 | -1.17 | -0.904 | -0.03 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -7.64 | -6.88 | -4.87 | -5.2 | -4.53 |
Capital Expenditures | -2.34 | -3.96 | -0.919 | -0.228 | -0.129 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -0.035 | 0 | — | 0.02 | 0 |
Sale of Fixed Assets | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -2.38 | -3.96 | -0.919 | -0.207 | -0.129 |
Financing Cash Flow Items | -1.83 | -0.012 | -0.001 | 0 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 20.3 | 8.01 | 2.38 | 7.78 | -0.93 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 10.3 | -2.81 | -3.4 | 2.37 | -5.59 |